189
Participants
Start Date
December 19, 2018
Primary Completion Date
July 18, 2023
Study Completion Date
July 18, 2023
Durvalumab + Oleclumab
Durvalumab + Oleclumab
Durvalumab
Durvalumab
Durvalumab + Monalizumab
Durvalumab + Monalizumab
Research Site, Taichung
Research Site, New York
Research Site, New York
Research Site, Castellon
Research Site, Marseille
Research Site, A Coruña
Research Site, La Rochelle
Research Site, Gettysburg
Research Site, Lancaster
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Milan
Research Site, Milan
Research Site, Rosedale
Research Site, Richmond
Research Site, Cremona
Research Site, Madrid
Research Site, Málaga
Research Site, Brest
Research Site, Toulouse
Research Site, Orlando
Research Site, Bordeaux
Research Site, Winter Haven
Research Site, Rennes
Research Site, Memphis
Research Site, Germantown
Research Site, Louisville
Research Site, Lexington
Research Site, Valencia
Research Site, Ravenna
Research Site, Siena
Research Site, Sioux Falls
Research Site, Lille
Research Site, Chiayi City
Research Site, Strasbourg
Research Site, Wichita
Research Site, Lincoln
Research Site, Lyon
Research Site, Pierre-Bénite
Research Site, Bron
Research Site, Covington
Research Site, Baton Rouge
Research Site, Tyler
Research Site, Salt Lake City
Research Site, Limoges
Research Site, Palermo
Research Site, Duarte
Research Site, Anaheim
Research Site, Créteil
Research Site, Catania
Research Site, Sacramento
Research Site, Tacoma
Research Site, New Haven
Research Site, West Haven
Research Site, Portland
Research Site, Edmonton
Research Site, Toronto
Research Site, Montreal
Research Site, Nice
Research Site, Hong Kong
Research Site, Jordan
Research Site, Kowloon
Research Site, Gdynia
Research Site, Lodz
Research Site, Lodz
Research Site, Lisbon
Research Site, Lisbon
Research Site, Porto
Research Site, Porto
Research Site, Badajoz
Research Site, Barcelona
Research Site, Barcelona
Research Site, Barcelona
Lead Sponsor
MedImmune LLC
INDUSTRY